PND-1186

  • CAT Number: I000311
  • CAS Number: 1061353-68-1
  • Molecular Formula: C25H26F3N5O3
  • Molecular Weight: 501.5
  • Purity: ≥95%
Inquiry Now

PND-1186 (CAT: I000311) is a potent FAK (focal adhesion kinase) inhibitor that has been developed as an anti-tumor drug for cancer therapy. In vitro studies have shown that PND-1186 inhibits FAK phosphorylation, leading to the inhibition of cell movement and the promotion of cell apoptosis in breast carcinoma cells. It has demonstrated limited effects on cell proliferation but has shown efficacy in blocking tumor growth and metastasis in vivo. PND-1186 has been well-tolerated in preclinical studies, and clinical trials are being conducted to evaluate its safety and efficacy in patients with metastatic non-hematological malignancies.


Catalog Number I000311
CAS Number 1061353-68-1
Synonyms

2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide

Molecular Formula C25H26F3N5O3
Purity ≥95%
Target FAK
Solubility DMSO: ≥ 34 mg/mL
Storage Store at -20°C
Overview of Clinical Research

<p>
<span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>PND-1186 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).</span></span></span></p>

IC50 1.5 nM
IUPAC Name 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide
InChI InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32)
InChIKey IGUBBWJDMLCRIK-UHFFFAOYSA-N
SMILES CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC
Reference

<br />
1:PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Schaller MD, Frisch SM.Cancer Biol Ther. 2010 May 15;9(10):791-3. Epub 2010 May 8. No abstract available. PMID: 20364110<br />
2:Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, Phillips A, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.Cancer Biol Ther. 2010 May 15;9(10):778-90. PMID: 20234193 Free PMC Article<br />
3:PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C, Patel N, Kwok C, McMahon G, Stupack DG, Schlaepfer DD.Cancer Biol Ther. 2010 May 15;9(10):764-77. PMID: 20234191 Free PMC Article

Request a Quote